International uniform response criteria for multiple myeloma

Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel, +27

Leukemia

Hematological MalignancyOncologyMalignant Blood DisorderHematologyMultiple Myeloma +1

Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery

Janina Ratajczak, Katarzyna Miękus, Magda Kucia, +4

Leukemia

Embryonic Stem CellDevelopmental BiologyHematopoietic ProgenitorsMedicineStem Cell Mobilization +9

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

Torsten Haferlach, Yasunobu Nagata, Vera Grossmann, +23

Leukemia

Genetic LesionsHematological MalignancyGenetic AberrationsGenetic DisorderMedicine +11

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Shaji Kumar, Angela Dispenzieri, Martha Q. Lacy, +13

Leukemia

Hematological MalignancyContinued ImprovementAgingGeriatricsLongevity +8

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Andreas Hochhaus, Sebastian Kreil, A. Corbin, +8

Leukemia

ChromatinGenome InstabilityCell DivisionCytogeneticsChromatin Remodeling +7

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Jacques J. M. van Dongen, Ludovic Lhermitte, Sebastian Böttcher, +20

Leukemia

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

Emmanuel Beillard, Niels Pallisgaard, Vincent H. J. van der Velden, +12

Leukemia

Hematological MalignancyPolymerase Chain ReactionPrognostic BiomarkersMolecular Diagnostic TechniquesResidual Disease Detection +9

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Andreas Hochhaus, S G O'Brien, François Guilhot, +11

Leukemia

Hematological MalignancyChronic Myeloid LeukemiaMedicineHematologyMyeloid Neoplasia +5

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes, +14

Leukemia

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

Daniel Sommermeyer, Michael Hudecek, Paula L. Kosasih, +4

Leukemia

Superior Antitumor ReactivityTumor ImmunologyCancer ImmunosurveillanceAutoimmune DiseaseMedicine +8